SD BioSensor, Inc

KSE 137310.KS

SD BioSensor, Inc Shares (Diluted, Weighted) for the year ending December 31, 2023: 110,859,665

SD BioSensor, Inc Shares (Diluted, Weighted) is 110,859,665 for the year ending December 31, 2023, a 9.44% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
  • SD BioSensor, Inc Shares (Diluted, Weighted) for the year ending December 31, 2022 was 101,298,929, a 3.87% change year over year.
  • SD BioSensor, Inc Shares (Diluted, Weighted) for the year ending December 31, 2021 was 97,521,156, a -5.10% change year over year.
  • SD BioSensor, Inc Shares (Diluted, Weighted) for the year ending December 31, 2020 was 102,761,549, a 0.00% change year over year.
  • SD BioSensor, Inc Shares (Diluted, Weighted) for the year ending December 31, 2019 was 102,761,549, a 0.00% change year over year.
Key data
Date Shares (Diluted, Weighted) Revenue Cost of Revenue Gross Profit
Market news
Loading...
KSE: 137310.KS

SD BioSensor, Inc

CEO Hyo Keun Lee
IPO Date July 16, 2021
Location South Korea
Headquarters 16 Deokyeong-daero
Employees 576
Sector Health Care
Industries
Description

SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.

Similar companies

323410.KS

KakaoBank Corp.

USD 14.39

0.74%

068270.KS

Celltrion, Inc.

USD 125.83

1.12%

361610.KS

SK IE Technology Co., Ltd.

USD 17.39

3.58%

326030.KS

SK Biopharmaceuticals Co., Ltd.

USD 75.63

-3.02%

302440.KS

SK bioscience Co.,Ltd.

USD 33.55

-1.07%

StockViz Staff

January 15, 2025

Any question? Send us an email